Get the Stockscreener App
1.74
1.14%
-0.02
Propanc Biopharma Inc stock is traded at $1.74, with a volume of 90,856.
It is down -1.14% in the last 24 hours and down -36.67% over the past month.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
See More
Previous Close:
$1.76
Open:
$1.805
24h Volume:
90,856
Relative Volume:
0.70
Market Cap:
$3.96M
Revenue:
-
Net Income/Loss:
$-18.36M
P/E Ratio:
-1.3105
EPS:
-1.3277
Net Cash Flow:
$-4.29M
1W Performance:
-13.22%
1M Performance:
-36.67%
6M Performance:
-91.36%
1Y Performance:
+0.00%
1-Day Range:
$1.70
$1.9558
1-Week Range:
$1.67
$2.02
52-Week Range:
$1.5557
$234.00
Propanc Biopharma Inc Stock (PPCB) Company Profile
Name
Propanc Biopharma Inc
Sector
Industry
Phone
61-03-9882-0780
Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.50 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.54 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Stock (PPCB) Latest News
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Earnings Outlook: Key Metrics for Q3 2025Post-Announcement Reaction - Newser
PPCB Stock Price, Quote & Chart | PROPANC BIOPHARMA INC (NASDAQ:PPCB) - ChartMill
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade - The Manila Times
Propanc Biopharma to file CTA in Australia for phase 1b study in 30-40 advanced cancer patients - marketscreener.com
Propanc Biopharma, Inc. CEO Forecasts Medical Breakthroughs Against Pancreatic Cancer Over Next Decade - Quiver Quantitative
Propanc pancreatic cancer drug saw 3 of 4 patients outlive life expectancy - Stock Titan
Propanc engages CDMO for GMP manufacture of cancer drug PRP By Investing.com - Investing.com Australia
Propanc engages CDMO for GMP manufacture of cancer drug PRP - Investing.com UK
Propanc Biopharma engages European CDMO for GMP production of PRP - TipRanks
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 3040 Advanced Cancer Patients - The Manila Times
Once-weekly proenzyme cancer therapy nears first tests in humans - Stock Titan
Propanc Biopharma (PPCB) Stock: Up +21.18%, Key Resistance at $2.16 2026-05-18Sector Analysis - newser.com
Propanc Biopharma reports Q3 results, secures financing - Investing.com UK
Propanc Biopharma reports Q3 results, secures financing By Investing.com - Investing.com Nigeria
Propanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate Developments - Quiver Quantitative
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results - marketscreener.com
Propanc moves to world-first cancer trial and anti-aging research - Stock Titan
Propanc Biopharma, Inc. 3Q 2026: Revenue $0 Net loss $(6.36M), EPS $(0.28) — 10-Q Summary - TradingView
Propanc Biopharma (PPCB) posts Q3 2026 loss and flags going concern risk - Stock Titan
Propanc Biopharma to Implement 1-for-25 Reverse Stock Split >PPCB - Moomoo
25 Propanc shares become 1 in Nasdaq bid-price compliance move - Stock Titan
Propanc Biopharma announces 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans - The Manila Times
Propanc Biopharma announces 1-for-25 reverse stock split - Investing.com
Propanc Biopharma, Inc. Announces 1-for-25 Reverse Stock Split to Enhance Nasdaq Compliance - Quiver Quantitative
Propanc Biopharma implements reverse stock split to support continued Nasdaq listing and growth plans - marketscreener.com
The supply chain story behind Propanc Biopharma (PPCB) earnings |Crowd Trend Signals - newser.com
Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital - MSN
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB - The Joplin Globe
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Propanc Biopharma Incfiles to offer resale of up to 15 million shares of common stock by selling stockholderSEC filing - marketscreener.com
Propanc Biopharma (PPCB) files S-1 for 15M-share resale from Series C preferred - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
PPCB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Propanc Biopharma (PPCB) approves restricted grants, reverse split 1:10–1:30 - Stock Titan
Propanc Biopharma, Inc. (PPCB) - Minichart
What should investors watch in Propanc Biopharma (PPCB) Stock | Price at $0.10, Down 3.30%Buy Signals - Newser
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - BioSpace
Propanc extends 17-year Spain research tie to study aging and cancer - Stock Titan
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer - GlobeNewswire
Propanc Biopharma Inc Stock (PPCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):